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Abstract The changes in phosphoproteins purified with the
affinity peptide p9CKShs1 were analyzed from extracts of
regenerating rat livers in order to define some G1 and G1/S
regulations characteristic of mature hepatocytes stimulated to
proliferate. We observed a 47 kDa phosphoprotein that occurred
first at the end of G1 before peaking in the S phase. P47 was also
found to be phosphorylated in late G1 in primary hepatocyte
cultures stimulated with mitogens. P47 was still phosphorylated
in extracts depleted of Cdc2, but to a lesser extent after Cdk2
depletion. This phosphoprotein was identified as Skp2. (i) P47
shared the same electrophoretic mobility than Skp2, a cell cycle
protein essential for S phase entry in human fibroblasts; (ii)
Skp2, like P47, started to be expressed and was highly
phosphorylated during the G1/S transition of hepatocytes
stimulated to proliferate in vivo and in vitro; (iii) P47 was
specifically immunoprecipitated by an antibody directed against
Skp2. In addition, cyclin A/Cdk2 complexes from regenerating
liver clearly interacted with Skp2. This is the first demonstration
that Skp2 is induced and phosphorylated in the late G1 and S
phase of hepatocytes in vivo in regenerating liver as well as in
vitro in mitogen-stimulated hepatocytes.
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1. Introduction
Normal hepatocytes are usually quiescent cells in vivo, but
in contrast to most other cell types, they retain the ability to
synchronously get into the active part of the cell cycle after
liver cell loss. This is exempli¢ed by the regeneration process
following partial hepatectomy (PHT) [1]. This model is char-
acterized by a particularly long G1 phase that can be analyzed
and dissected into distinct steps. Immediately after PHT, hep-
atocytes enter in a state of pre-replicative competence before
they can fully respond to growth factor. This priming step is
an initiating event presumably induced by TNF-K and other
cytokines mainly IL-1 and IL-6 [2^4]. Then, these ‘initiated
cells’ require a growth factor stimulation to progress further
in the late G1 and S phase. Di¡erent growth factors and
hormones (HGF, EGF, TGF-K, insulin, norepinephrine) ap-
pear to play an important role in this regenerating process
[5^9]. This process can be mimicked in vitro. Both EGF and
HGF have been shown to stimulate signal transduction and
MAP kinase cascade activity in rat hepatocytes in vitro
[10^14]. A growth factor-dependent restriction point has
been localized in vitro in mid-late G1 in primary rat hepato-
cytes [15]. These two models give us the opportunity to look
at the events occurring during the G1 phase progression of
highly di¡erentiated hepatocytes.
The eukaryotic cell cycle molecular machinery is based on
protein complexes composed of regulatory subunits (cyclins),
catalytic subunits (Cdks for cyclin-dependent kinases) and
some associated proteins [16^19]. Major elements in check-
point controls acting at the G1 progression and G1/S transi-
tion are kinases and phosphatases that determine the state of
phosphorylation of the Cdk/cyclin complexes (for review see
[20]). The mechanisms of regulation that speci¢cally control
progression from the priming step to the late G1 phase in
hepatocytes remain poorly elucidated. In this work, we used
the strong a⁄nity of the Cdks for the peptide p9CKShs1 (p9),
allowing to purify the Cdks and Cdk-associated proteins in
non-denaturing conditions in order to isolate the proteins in-
teracting with these complexes in hepatocytes. This peptide is
the mammalian homologue of CKS1 from Saccharomyces
cerevisiae and p13suc1 from Schizosaccharomyces pombe,
which has been used extensively to purify Cdc2, Cdk2 and
their associated proteins [21,22].
We describe here a protein of 47 kDa (P47), which phos-
phorylation occurred in the late G1 and G1/S phase transition
of the hepatocyte cell cycle. Analysis of its biochemical char-
acteristics led us to further de¢ne the molecule and to ques-
tion whether it could correspond to the Skp2 phosphoprotein
¢rstly described by Zhang et al. in ¢broblasts [19] but never
reported in highly di¡erentiated normal cells such as hepato-
cytes.
2. Materials and methods
2.1. Chemicals
[Q-32P]ATP (3000 Ci/mmol), [32P]H3PO4 (10 mCi/ml) and methyl-
[3H]thymidine (5 Ci/mmol) were from Amersham (Rainham, UK);
protein A-Sepharose CL-4B, sephacryl S-100-HR and CNBr-activated
Sepharose 4B were from Pharmacia; recombinant human EGF was
from Promega (Madison, WI, USA). Bead bu¡er and bu¡er C were as
described [23].
2.2. Antibodies
Anti-p34Cdc2 and anti-p33Cdk2 are rabbit polyclonal antiserum
directed against C-terminal portions of human p34Cdc2 and
p33Cdk2 [23]. Anti-human cyclin A antibodies raised against the
full length cyclin A are obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Two antibodies (Santa Cruz, CA, USA),
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anti-Skp2 p45 goat polyclonal antiserum against the carboxy-terminus
of the human Skp2 and anti-Skp2 against the full lenght molecule,
were used for immunoblotting and immunoprecipitation of translated
products, respectively.
2.3. Animals and cell cultures
PHT (two-thirds) was performed according to the method of Hig-
gins and Anderson [1] in accordance to French laws and regulation.
Hepatocytes were isolated from rat livers by the two-step perfusion
procedure [24]. Cells were plated in minimum essential medium
(MEM)-199 (3:1) (v/v), added with 10% fetal calf serum (FCS). 4 h
later and every day, it was renewed by a medium without FCS, sup-
plemented with EGF (50 ng/ml) and sodium pyruvate (10 mM). NIH-
3T3, FAZA 967, FAO were cultured in a mixture of Ham F12/NCTC
199 (1:1). Immortalized epithelial liver cells (RLEC) and HTC hep-
atoma cells were cultured in Williams medium and DMEM, respec-
tively. All media were supplemented with 10% FCS.
2.4. [3H]Thymidine incorporation
The rate of DNA synthesis was measured in animals following PHT
or sham operation as described [23]. In hepatocyte cultures, 2 WCi of
methyl-[3H]thymidine was added for 24 h periods prior to cell harvest-
ing at the indicated times. Incorporation was measured by scintillation
counting after trichloroacetic acid precipitation.
2.5. Cdk-cyclin complexes preparation and phosphorylation
p9 was puri¢ed by gel ¢ltration on sephacryl S-100 and coupled to
CNBr-activated Sepharose 4B [25]. Brie£y, protein extracts (100 Wg)
were bound to p9 beads for 60 min at 4‡C, pelleted and washed [23].
Thereafter, p9 bead pellets were resuspended in 50 Wl of C phospho-
rylation bu¡er containing 10 WCi [Q-32P]ATP for 1 h at 30‡C. The
reaction was stopped by 60 Wl of sample bu¡er and proteins were
separated on 10% SDS-PAGE [26]. To identify alkali resistant phos-
phoproteins, the gels were soaked in 2 M NaOH for 1 h at 55‡C [27]
prior to drying and autoradiography. The phosphoamino acid was
analyzed on cellulose thin layer plates as previously described [28].
2.6. [32P]H3PO4 incorporation
At indicated times, hepatocytes were incubated for 1 h in culture
medium containing 250 WCi [32P]H3PO4. Then, the proteins were
bound to p9 beads as described above.
2.7. Immunoblotting and immunoprecipitations.
After SDS-PAGE, proteins were transferred onto nitrocellulose
membranes according to established protocols. Immunoprecipitations
were performed for 2 h at room temperature in the presence of protein
A-Sepharose. For immunodepletions, the supernatant was re-immu-
noprecipitated four times. The ¢nal supernatants were bound to p9
beads and phosphorylated as described above.
2.8. cDNA cloning, reverse transcription (RT)-PCR and Northern
blotting analyses
Rat Skp2 cDNA probe was obtained by RT-PCR based on the
human sequence data [19] using primers 5P-TAGACAACTGGG-
CTTTTGCAGAGTC-3P and 5P-CTTCCGGATGAGCTGCTCTTG-
GGAA-3P from HTC cells.
Rat Skp2 PCR product was cloned and DNA sequencing was per-
formed. Primers 5P-CTGCAGAATCTGAGTCTGGAAGGC-3P and
5P-TAGTGTGGGGATTTCTCCGAGTTC-3P speci¢c for rat Skp2
were used for direct semi-quantitative Skp2 RT-PCR analysis. Total
RNA extracted from hepatocytes stimulated or not by EGF/pyruvate
and from liver cell lines were used for Northern blotting as described
previously [15].
The quality of cDNA was con¢rmed by PCR ampli¢cation of a
similar-sized fragment of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
2.9. Binding assays
Cdk2 and cyclin A immunoprecipitations were performed by incu-
bating 0.5 mg of 24 h liver extract in binding bu¡er (20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM EDTA,
1 mM dithiothreitol and 5 Wg/ml aprotinin, leupeptin and soybean
trypsin) with speci¢c antibody at 4‡C overnight and then, in the
presence of protein A-Sepharose for 1 h at 4‡C. The samples
were then pelleted and washed three times. Human full length
Skp2 cDNA was obtained using primers 5P-TAGACAACTGG-
GCTTTTGCAGAGTC-3P and 5P-GCAGCTCTGCAAGTTTAATG-
CACGT-3P. [35S]methionine-labelled full length human Skp2 (Skp2
(wt)), was produced in vitro using the TNT T7 Coupled Reticulocyte
Lysate System (Promega) according to the manufacturer’s instruc-
tions. A clone of Skp2 with a stop codon at positions 630^632, de-
termined from the translation initiation site, was used to generate a
C-terminal truncated form (Skp2 (vC)). 10 Wl translation product was
mixed with Cdk2 or cyclin A immunoprecipitates, diluted to 150 Wl
with binding bu¡er. The mixture was incubated on ice for 1 h. Beads
were washed three times, then, separated on a 15% SDS-polyacryl-
amide gel, ¢xed, dried and subjected to autoradiography.
3. Results
3.1. P47 phosphoprotein is observed in the late G1 phase of
regenerating liver
[3H]Thymidine incorporation was measured at di¡erent
times after PHT allowing to de¢ne the G1 and S phases of
the cell cycle in this model. Fig. 1A shows that the DNA
synthesis starts at 20 h after surgery and peaked at around
24 h. This localizes the G1/S transition of these cells 18^20 h
following PHT.
In order to select proteins associated with Cdks/cyclins dur-
Fig. 1. Phosphorylation of p9CKShs1-associated protein complexes
extracted from regenerating rat livers. (A) Time course of
[3H]thymidine incorporation into DNA of regenerating liver follow-
ing PHT. (B) Alkaline resistant phosphoprotein patterns of proteins
puri¢ed by binding to p9(CKShs1) beads at the indicated times. (C)
p9 minus beads-associated alkaline resistant phosphoproteins from
regenerating rat liver. (D) p9 bead-associated phosphoproteins from
non-regenerative liver (sham) at the indicated times after surgery:
P47 from 24 h regenerating liver puri¢ed with p9 beads as a posi-
tive control (C). (E) Phosphoamino acid analysis of P47. Phospho-
amino acids were analyzed by electrophoresis (E) followed by chro-
matography (C). T, phosphothreonine; Y, phosphotyrosine.
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ing the G1 progression and S phase of regenerating livers, we
puri¢ed them by coupling tissue extracts from liver, at di¡er-
ent times after PHT, with the small peptide p9(CKShs1)-
coated beads. The proteins were phosphorylated in vitro
with [Q-32P]ATP at 30‡C for 60 min. We chose to perform
alkaline digestion on SDS-PAGE gels because of the high
frequency of cell cycle-associated proteins to be phosphoryl-
ated onto threonine and tyrosine residues. Indeed, phospho-
tyrosine as well phosphothreonine but not phosphoserine res-
idues were resistant to a di¡erent degree to alkaline exposure
[27]. Among phosphoproteins, only a few were found to resist
alkaline digestion: a 47 kDa protein (P47) was strongly phos-
phorylated and a 52 kDa protein to a lesser extent (Fig. 1B).
These proteins were ¢rst identi¢ed at the end of G1 and
peaked in the middle of the S phase. A 49 kDa phosphopro-
tein was also present in the normal liver but disappeared very
soon after PHT.
The speci¢city of these phosphoproteins regarding p9 bind-
ing was established by analyzing the pattern of phosphopro-
teins bound to pure Sepharose beads. The 49 kDa phospho-
protein from normal liver was found to be phosphorylated
revealing its unspeci¢c binding to p9 beads (Fig. 1C), whereas
P47 phosphoprotein could not be seen. In addition, extracts
from non-regenerating liver from sham-operated animals
bound to p9 beads did not show any alkaline resistant phos-
phoprotein (Fig. 1D).
To evidence threonine and tyrosine phosphorylation sites of
p47, we performed amino acid analysis of this alkaline resist-
ant phosphoprotein by excising the band from the SDS-
PAGE gel, hydrolyzing with HCl and resolving it on two-
dimensional cellulose thin layer plates. We found that P47
was phosphorylated on two residues (Fig. 1E).
3.2. P47 phosphorylation also occurs in late G1 in mitogen-
stimulated hepatocyte primary cultures
We previously showed that rat hepatocytes in primary cul-
tures replicated their DNA after EGF/sodium pyruvate stim-
ulation [15]. In continuous presence of the mitogen, the cells
entered the S phase 48^50 h after seeding and the peak of
DNA synthesis occurred at 96 h (Fig. 2A). A phosphoprotein
bound to p9 beads and co-migrating with P47 was detected in
these cells, ¢rst at 48 h in the late G1 phase and accumulated
thereafter in the S phase (Fig. 2B). Furthermore, phosphoryl-
ation activity was assessed by incubating hepatocyte cultures
in the presence of [32P]H3PO4. A p9-bound phosphoprotein
similar to P47 also appeared at 48 h of culture in the mitogen-
stimulated hepatocytes but not in control unstimulated cells
(Fig. 2C). Our results show that P47 is phosphorylated in vivo
as well as in vitro in the late G1 phase of proliferating hep-
atocytes.
In order to look for the presence of P47 in other cell types
Fig. 2. Phosphorylation of p9CKShs1-associated protein complexes
from mitogen-stimulated primary rat hepatocyte cultures. (A) Time
course of [3H]thymidine incorporation into DNA of hepatocytes
stimulated (hatched) or not (black) with EGF/pyruvate. (B) Alkaline
resistant phosphorylation proteins puri¢ed with p9 beads and ex-
tracted from mitogen-stimulated cultures at the indicated times after
seeding. (C) [32P]Orthophosphate-labelled proteins puri¢ed with p9
beads from 24 h (1, 2) and 48 h (3, 4) hepatocyte cultures stimu-
lated (2, 4) or not (1, 3) with EGF (C, P47 control from 24 h regen-
erating liver).
Fig. 3. Phosphorylation of G1-synchronized NIH-3T3 mouse ¢bro-
blasts. (A) Time course of [3H]thymidine incorporation into DNA
of NIH-3T3 cells synchronized for 24 h with 10 mM sodium buty-
rate and kept blocked (black) or switched at time 0 to 10% FCS
(hatched) in order to stimulate cell cycle progression. (B) Alkaline
resistant phosphoproteins from p9-puri¢ed proteins extracted from
NIH-3T3 cells at the indicated times following release of the buty-
rate blockage (c, control from 24 h regenerating liver extract). (C)
Alkaline resistant phosphoproteins from NIH-3T3 cells maintained
blocked (16B, 24B) in butyrate or released in FCS (16S, 24S) at
16 and 24 h following medium change.
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in vitro, we chose to block NIH-3T3 mouse ¢broblasts in
early G1 by sodium butyrate (10 mM) and serum deprivation
and to analyze the G1 and S phase progression of these cells
after release of this block by 10% FCS addition. The G1/S
transition occurred 12/16 h after the release and was followed
by a well-synchronized S phase (Fig. 3A). Several phospho-
proteins were found to resist alkali treatment and a phospho-
protein co-migrating with the rat liver P47 was also detected
in NIH-3T3 synchronized ¢broblasts (Fig. 3B). Phosphoryla-
tion of the protein appeared in the late G1 phase (12 h),
peaked in the S phase (20 h) and decreased thereafter. The
cells that remained blocked in the early G1 phase in the pres-
ence of butyrate never showed any evidence of P47 phos-
phorylation (Fig. 3C).
3.3. P47 could interact with Cdk2
Since p9 is known to bind di¡erent cell cycle proteins, we
looked if there was any relation between p47 and some well-
characterized kinases, i.e. Cdc2 and Cdk2. These protein kin-
ases have been shown to be expressed in rat hepatocytes in
relation to the cell cycle and their histone H1 kinase activity
was found in the S phase [15].
Therefore, we performed selective immunodepletions of
each protein to determine if these protein kinases were part
of a complex to which phosphorylated P47 could be associ-
ated. We ¢rst cleared Cdc2 or Cdk2 from tissue extracts as
evidenced by Western blotting (Fig. 4A, B) and then, we per-
formed p9 binding. We showed that phosphorylation of P47
bound to p9 was not signi¢cantly modi¢ed in Cdc2-depleted
extracts (Fig. 4C) while it was signi¢cantly decreased after
Cdk2 depletion, indicating that this kinase could interact
with P47.
3.4. Skp2 is induced, phosphorylated and interacting with the
Cdk2/cyclin A complex upon S transition of regenerating
liver in vivo
Skp2 has been described to occur in the S phase of normal
and transformed ¢broblasts as a phosphoprotein of 45 kDa,
which interacts with the Cdk2/cyclin A complex [19]. In order
to see whether P47 could be Skp2, we looked ¢rst at the
appearance of Skp2 in regenerating liver and compared its
electrophoretic mobility to that of P47. Then, we deviced ex-
periments to analyze the ability of the anti-Skp2 antibody to
immunoprecipitate P47. Then, we looked at the interactions
between Skp2, cyclin A and Cdk2 in 24 h regenerating liver.
As shown in Fig. 5A, the Skp2 expression kinetics were
identical to that of P47 phosphorylation, it started to be de-
tected 20 h after PHT at a time corresponding to the G1/S
transition. Thereafter, the protein level increased in the S
phase, i.e. 24 h after PHT. In addition, Skp2 immunoprecipi-
tation from cell extracts 4 and 24 h after PHT revealed one
alkaline resistant protein in the 24 h extract sharing the same
electrophoretic mobility as P47 (Fig. 5B). As expected, no
Skp2 phosphorylation could be detected with a non-immune
serum.
Conversely, P47-phosphorylated protein bound to p9 beads
from 24 h PHT extracts was solubilized in a mixture of de-
tergent (TX100 1%, DOC 1%, SDS 0,01%) and immunopre-
cipitated with Skp2 antibody. As shown in Fig. 5C, a charac-
teristic P47 band was evidenced with Skp2 antibody while no
band could be detected with a non-immune serum.
Finally, Cdk2/cyclin A complex interaction with Skp2 was
demonstrated in regenerating rat liver. Two human Skp2
Fig. 4. Phosphorylation of P47 from Cdc2- and Cdk2-immunode-
pleted 24 h regenerating liver (-Cdc2, -Cdk2). (A) Anti-Cdc2 and
(B) anti-Cdk2 Western blots of Cdc2- and Cdk2-immunodepleted 24
h regenerating liver extracts. (C) Phosphorylation of p9-associated
proteins following immunodepletion of Cdc2 and Cdk2 (NIS, con-
trol depletion with a non-immune serum).
Fig. 5. Skp2 protein expression and phosphorylation in regenerating
liver. (A) Western blotting analysis of Skp2 in regenerating liver at
the indicated times after PHT. (B) Alkaline resistant phosphoryla-
tion after immunoprecipitation by Skp2 antiserum at 14 h (a) and
24 h (b) following PHT. Controls from non-immune serum at the
same times (c, d) and P47 from the 24 h regenerating liver (e). (C)
Immunoprecipitation of P47 by Skp2 antiserum. P47 from 24 h re-
generating liver (a). P47 was solubilized by a mixture of non-dena-
turant detergent and the residual P47 on p9 beads was analyzed (b).
Then, the solubilized P47 was immunoprecipitated by Skp2 antise-
rum (c) or a non-immune serum (d).
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cDNA probes obtained by RT-PCR and corresponding to the
full length protein and a truncated form of the molecule were
selected. These clones were translated in a reticulocyte lysate
system in the presence of [35S]methionine and immunoprecip-
itated by speci¢c polyclonal antibody against the full length
Skp2 of human origin (Fig. 6A). This polyclonal antibody
recognized two proteins corresponding to the expected sizes.
Then, we performed immunoprecipitations of 24 h regener-
ating liver extracts using speci¢c antibodies against Cdk2 or
cyclin A. Immunoprecipitates were incubated with the [35S]-
labelled Skp2 proteins, washed and analyzed by SDS-PAGE.
As shown in Fig. 6B, cyclin A and Cdk2 complexes were able
to bind the full length Skp2 protein but not the truncated
form. No protein could be detected with a non-immune se-
rum.
3.5. Skp2 mRNA expression is induced in proliferating
hepatocytes in vitro and hepatoma cells
To provide additional evidence on the expression kinetics of
Skp2 in growth-stimulated hepatocytes, ¢rst, we looked at the
Skp2 mRNA expression in a primary culture of hepatocytes
stimulated by EGF by using Northern blotting. As shown in
Fig. 7A, Skp2 mRNA was expressed in EGF-stimulated cells
according to their progression in the G1 phase while non-
stimulated hepatocytes did not show a detectable level of
Skp2 mRNA. Secondly, semi-quantitative RT-PCR has al-
lowed to evidence an increased Skp2 PCR product ampli¢ca-
tion in proliferating hepatocytes while a low level was ob-
served in unstimulated cell cultures (Fig. 7B).
Since Skp2 is known to greatly increase in many trans-
formed cells [19,29], we looked at its expression in di¡erent
immortalized (RLEC) and transformed (HTC, FAZA, FAO)
liver cell lines (Fig. 7C). Skp2 mRNA was highly expressed in
all the actively growing hepatoma cell lines analyzed, although
di¡erences in the steady state levels were observed from one
line to the other. Furthermore, proliferating immortalized rat
liver epithelial cells (RLEC) appeared to express a higher level
of Skp2 mRNA than the resting cells at con£uency, showing
that Skp2 expression was also correlated with a growing ac-
tivity in these cells.
4. Discussion
The approach used in this study allowed us to pinpoint a
phosphoprotein associated to the proteins, which controls the
cell cycle at the G1/S transition of proliferating hepatocytes.
We identi¢ed this phosphoprotein as Skp2 and showed for the
¢rst time that this protein was induced and phosphorylated in
vivo in the late G1 and S phase of regenerating liver as well as
in vitro in mitogen-stimulated normal hepatocytes.
It has been established for a long time that cyclins, Cdks
and associated proteins, which are actors of prime importance
in the cell cycle, are regulated through phosphorylation
changes of some of their residues. An increased level of cyclin
D1, in mid-late G1, correlates with cell cycle progression
through the mitogen-associated restriction point. In late G1
and S phase, Cdc2 and Cdk2 kinases are activated in associ-
ation to cyclins A, B and E [15,23,30,31]. All proteins inter-
Fig. 6. Liver Cdk2/cyclin A S phase interaction with Skp2. (A) Im-
munoprecipitation of translated products of truncated Skp2 (vC) (1,
2) or full length Skp2 (wt) (3, 4) by a polyclonal antibody against
human Skp2 (2, 4). Controls with a non-immune serum (1, 3). (B)
Binding of [35S]-labelled truncated (3) or full length (4^6) Skp2 pro-
teins to cyclin A (3, 4), Cdk2 (5) from 24 h regenerating liver ex-
tracts and to control extract with a non-immune serum (6). Electro-
phoretic migration of Skp2 (vC) (1) and Skp2 (wt) (2) as control
(input).
Fig. 7. Skp2 Northern blotting (A, C) and RT-PCR analysis (B).
Total RNA was extracted at the indicated times from a primary
culture of hepatocytes stimulated (+EGF) or not (3EGF) by
growth factor 4 h after seeding. Skp2 Northern blotting (A) and
RT-PCR (B) analysis. Control: PCR ampli¢cation of a similar-sized
fragment of GAPDH. (C) Skp2 Northern blotting analysis of total
RNA extracted from a 4 h (1) and 48 h (2) unstimulated primary
culture of hepatocytes, proliferative hepatoma cells HTC (3), FAZA
(4), FAO (5) and immortalized liver epithelial cells (RLEC) in a
proliferative state (6) and at con£uency (7).
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acting with these complexes are not well-identi¢ed in hepato-
cyte and regulation mechanisms responsible for the ability of
these growth-arrested di¡erentiated cells to duplicate follow-
ing a growth signal remain poorly understood. The objective
of our study was to look at changes in phosphorylation of the
cell cycle proteins in order to identify some candidates for the
regulation of G1 progression and G1/S transition of prolifer-
ating hepatocytes. The use of p9CKShs1, in non-denaturing
conditions, enabled us to purify Cdk/cyclin complexes and
their associated proteins [22]. We focused our attention on
proteins phosphorylated on both threonine and tyrosine by
alkaline lysis of phosphoserine.
This strategy has allowed us to detect only a few alkaline
resistant proteins associated with p9 beads and among them, a
P47 phosphorylation started to be observed at the end of G1,
just prior to the S phase, where it reached a maximum. The
phosphorylated protein was speci¢cally associated with the
cell replication in growth-stimulated hepatocytes as shown
by its kinetics which are strictly correlating with cell progres-
sion through the G1 and S phase, using two di¡erent model
systems: regenerating rat liver and hepatocyte primary cul-
tures stimulated by a growth factor. Furthermore, by detect-
ing P47 at the end of G1 and peaking in the S phase of
synchronized NIH-3T3, we extend to non-hepatic cells the
expression and regulation of this cell cycle-associated protein.
Because of its molecular weight, we investigated whether P47
could be cyclin E or a MAP kinase (ERK 1 or ERK 2) using
speci¢c antibodies and we ruled out these possibilities. In
contrast, interestingly, we identi¢ed P47 as Skp2, a 45 kDa
protein in human cells. Several characteristics argue for Skp2
identi¢cation:
(i) The kinetics of Skp2 expression and phosphorylation in
hepatocytes were similar to those of P47 phosphorylation.
(ii) Similar characteristics in molecular weight and in sites
of phosphorylation on tyrosine and threonine residues in late
G1 were observed.
(iii) The ability of Skp2 antibody to recognize one protein
bound to a p9 bead and resistant to alkali treatment namely
P47 was clearly established.
Overall, from these data, evidence is provided for the ¢rst
time that Skp2 is expressed in normal adult hepatocytes and
its transcriptional regulation is strictly associated to the cell
cycle progression, its induction being located just before the
G1/S transition. Noteworthy, the fact that changes in the
phosphorylation status of the protein followed the same kin-
etics provides strong arguments in favor of a crucial role of
this molecule in the cell decision to undergo DNA synthesis.
It is important to note that P47 was also identi¢ed at a time
corresponding to the G1/S transition in [32P]H3PO4-labelled
hepatocytes stimulated by EGF, providing con¢rmation that
this protein was phosphorylated in late G1 in proliferating
hepatocytes in situ prior to any interactions with exogenous
p9 protein.
Skp2 was initially identi¢ed in transformed cells and in a
recent study, overexpression was found in 17 of 31 (55%)
human hepatocellular carcinomas [32]. Here, we also con¢rm
an overexpression of Skp2 mRNA in several hepatoma cell
lines. In addition, an expression associated with the prolifer-
ation is suggested in immortalized cells like RLEC.
Zhang et al. have characterized two proteins of 19 and 45
kDa (SKp1 and Skp2) that are essential elements of the Cdk2/
cyclin A S phase kinase in human ¢broblasts [19]. Further-
more, while Skp2 can inhibit the kinase activity of Cdk2/cy-
clin A toward histone H1, Skp2 itself appears to serve as a
substrate at the same time. Recently, Ser-76 was found to be
the major site of Skp2 phosphorylation by Cdk2/cyclin A [29].
In this report, we showed that proteins of the Cdk2/cyclin A S
phase complex of regenerating liver clearly interact with Skp2.
Moreover, immunodepletion of Cdk2 also evidenced that
Skp2 phosphorylation was, at least partly, dependent on the
presence of Cdk2, indicating that Cdk2 is one of the kinases
interacting with the Skp2 in di¡erentiated liver cells stimu-
lated to proliferate as it was described in dividing human
¢broblast and HeLa cells [19,29]. Untill now, Skp2 phospho-
rylation onto other sites than serine has not been reported.
Using an alkali resistant gel, we demonstrate here that Skp2
could also be phosphorylated on a threonine and tyrosine and
that this phosphorylation activity was strictly associated with
the cell cycle.
While the role of Skp2 in promoting the S phase is well-
established, the mechanism involved in this process is not yet
completely understood. Skp2 could be associated to the ubiq-
uitination machinery process by its F box domain interac-
tions. Indeed, recently, Lisztwan et al. have proposed that,
to promote the S phase, eukaryotic cells might use an ubiq-
uitin conjugation apparatus governed in part by periodic S
phase-speci¢c accumulation of the Skp2 subunit [33]. Skp2
belongs to the family of F box proteins which play a critical
role in ubiquitin-mediated protein degradation in S. cerevisiae
[34]. Moreover, the human Skp2/SKp1/Cul-1 complex is likely
to function as an E3 ligase to selectively target cyclin D and
P21 for ubiquitin-dependent protein degradation [35]. Our
study pinpoints Skp2 as a potential player in the G1/S tran-
sition and S phase of mature hepatocytes and, for the ¢rst
time, shows that Skp2 is regulated in a cell cycle-dependent
manner in normal highly di¡erentiated cells in vivo as well as
in vitro. Its role in the complex control machinery of prolif-
erating hepatocytes is presently under investigation.
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